These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 3139944)

  • 1. [Treatment of a hemorrhagic syndrome in severe von Willebrand disease in the presence of circulating anti-von-Willebrand-factor antibody].
    Monteagudo J; López Guillermo A; Castillo R
    Med Clin (Barc); 1988 May; 91(1):28-30. PubMed ID: 3139944
    [No Abstract]   [Full Text] [Related]  

  • 2. Continuous infusion of recombinant factor VIIa (NovoSeven) in the treatment of a patient with type III von Willebrand's disease and alloantibodies against von Willebrand factor.
    Grossmann RE; Geisen U; Schwender S; Keller F
    Thromb Haemost; 2000 Apr; 83(4):633-4. PubMed ID: 10780333
    [No Abstract]   [Full Text] [Related]  

  • 3. Management of von Willebrand's disease.
    Logan LJ
    Prog Clin Biol Res; 1990; 324():279-90. PubMed ID: 2106690
    [No Abstract]   [Full Text] [Related]  

  • 4. Posttransfusion anaphylactic reactions in a patient with severe von Willebrand disease: role of complement and alloantibodies to von Willebrand factor.
    Bergamaschini L; Mannucci PM; Federici AB; Coppola R; Guzzoni S; Agostoni A
    J Lab Clin Med; 1995 Mar; 125(3):348-55. PubMed ID: 7897302
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibodies to factor VIII-von Willebrand factor in congenital and acquired von Willebrand's disease.
    Mannucci PM; Mari D
    Prog Clin Biol Res; 1984; 150():109-22. PubMed ID: 6431422
    [No Abstract]   [Full Text] [Related]  

  • 6. [Spectrum of von Willebrand-Jürgens syndrome. A study on 53 patients].
    Hasler K; Klink I
    Dtsch Med Wochenschr; 1985 Oct; 110(40):1531-4. PubMed ID: 3930195
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of von Willebrand's disease.
    Mannucci PM
    J Intern Med Suppl; 1997; 740():129-32. PubMed ID: 9350194
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Life-threatening reaction to factor VIII concentrate in a patient with severe von Willebrand disease and alloantibodies to von Willebrand factor.
    Mannucci PM; Tamaro G; Narchi G; Candotti G; Federici A; Altieri D; Tedesco F
    Eur J Haematol; 1987 Nov; 39(5):467-70. PubMed ID: 3121382
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Von Willebrand factor in high-purity factor VIII complex concentrates: chaperone protein or key to therapies? A meeting report.
    Federici AB; Mannucci PM; Marco P
    Haemophilia; 2008 Jan; 14(1):133-9. PubMed ID: 17941830
    [No Abstract]   [Full Text] [Related]  

  • 10. [Acquired von Willebrand syndrome with autoimmune hemolytic anemia].
    Sakai M; Shima M; Izumi Y; Shirahata A
    Rinsho Ketsueki; 2004 Mar; 45(3):223-7. PubMed ID: 15103936
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The factor VIII/von Willebrand factor ratio discriminates between reduced synthesis and increased clearance of von Willebrand factor.
    Eikenboom JC; Castaman G; Kamphuisen PW; Rosendaal FR; Bertina RM
    Thromb Haemost; 2002 Feb; 87(2):252-7. PubMed ID: 11859851
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Studies on molecular size distribution of factor VIII-related antigen in patients with Von Willebrand's disease and their parents].
    Mikami S; Nishino M; Yasui M; Okubo Y; Shima H; Fukui H
    Rinsho Ketsueki; 1982 Aug; 23(8):1198-204. PubMed ID: 6815349
    [No Abstract]   [Full Text] [Related]  

  • 13. Successful treatment with recombinant factor VIIa of therapy-resistant severe bleeding in a patient with acquired von Willebrand disease.
    Friederich PW; Wever PC; Briët E; Doorenbos CJ; Levi M
    Am J Hematol; 2001 Apr; 66(4):292-4. PubMed ID: 11279642
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and efficacy of continuous infusion of a combined factor VIII-von Willebrand factor (vWF) concentrate (Haemate-P) in patients with von Willebrand disease.
    Lubetsky A; Schulman S; Varon D; Martinowitz U; Kenet G; Gitel S; Inbal A
    Thromb Haemost; 1999 Feb; 81(2):229-33. PubMed ID: 10063997
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment and prevention of acute bleedings in von Willebrand disease--efficacy and safety of Wilate, a new generation von Willebrand factor/factor VIII concentrate.
    Berntorp E; Windyga J;
    Haemophilia; 2009 Jan; 15(1):122-30. PubMed ID: 19149848
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of partial gene deletions in type III von Willebrand disease with alloantibody inhibitors.
    Mancuso DJ; Tuley EA; Castillo R; de Bosch N; Mannucci PM; Sadler JE
    Thromb Haemost; 1994 Aug; 72(2):180-5. PubMed ID: 7831648
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of monoclonally-purified and recombinant factor VIII in patients with severe von Willebrand disease.
    Morfini M; Mannucci PM; Tenconi PM; Longo G; Mazzucconi MG; Rodeghiero F; Ciavarella N; De Rosa V; Arter A
    Thromb Haemost; 1993 Aug; 70(2):270-2. PubMed ID: 8236134
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of factor VIII/von Willebrand factor concentrate Alphanate in preventing excessive bleeding during surgery in subjects with von Willebrand disease.
    Rivard GE; Aledort L;
    Haemophilia; 2008 Mar; 14(2):271-5. PubMed ID: 18194310
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The factor VIII complex: hemophilia A and von Willebrand disease].
    Tobelem G; Rothschild C
    Sem Hop; 1982 Sep; 58(35):2032-6. PubMed ID: 6293093
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management of von Willebrand disease type 3 during pregnancy - 2 cases reports.
    Inocêncio G; Braga A; Azevedo S; Buchner G
    Eur Rev Med Pharmacol Sci; 2013 Nov; 17(21):2857-9. PubMed ID: 24254552
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.